Seven-years post allogeneic hematopoietic stem cell transplantation pure red cell aplastic anemia cured with daratumumab: A case report and review of literature

Table 1 Summary of daratumumab utilization in post-transplant major ABO mismatched hematopoietic stem cell transplantation and delayed red blood cell engraftment

Ref.	Age/sex	Diagnosis	Type of transplant	ABO mismatch (D/R)	Conditioning	Source	GVHD prophylaxis	CD34+ cells (× 106/kg)	Neutrophil	Platelet	Previous therapies	Initiation	Doses	Time to response
Grigg et al[15]	17/F	SAA	MSD	B/O	FLU + Cy + ATG	PBSC	Tacrolimus; MTX	3.34	D+14	D+11	Tapering of IST; Glucocorticoids; IVIG; Bortezomib	D+163	4	After 3rd doses
Chapuy et al[3]	72/M	MDS	MUD	A/O	RIC	PBSC	Tacrolimus; MTX	5.01	D+18	D+25	Tapering of IST; Glucocorticoids; Rituximab; Darbepoetin	D+390	6	After 1st dose
Bathini et al[5]	60/F	MDS	MUD	A/O	RIC	PBSC	Tacrolimus; MTX; ATG	6.0	D+11	D+18	Tapering of IST; Glucocorticoids; Rituximab; Bortezomib	D+411	4	After 1st dose
Rautenberg et al[4]	43/F	AML	MUD	A/O	MAC	PBSC	Tacrolimus; MMF	8.0	D+9	D+17	Tapering of IST; Rituximab	D+206	2	After 2nd dose
Salas et al[7]	34/M	AA	MSD	AB/O	RIC	PBSC	MTX; CSA	6.91	D+13	D+11	Tapering of IST; Rituximab; Glucocorticoids; PX; Bortezomib	D+700d	6	After 6th dose
Henig et al[8]	25/M	Chronic neutropenia	MSD	A/B	MAC	PBSC	MTX; CSA	7.9	D+23	D+12	Tapering of IST; Rituximab; Bortezomib	D+320	5	After 4th dose
Yates et al[9]	14/F	DOCK8 deficiency	Haplo	A/O	MAC	BM+PBSC	CTX; tacrolimus; MMF	9.3	D+15	D+22	Tapering of IST	D+397	3	After 3rd doses
Martino et al[10]	77/F	AML	NR	A/O	RIC	NR	Sirolimus tacrolimus	NR	NR	NR	NR	D+205	3	After 1st dose
Martino et al[10]	62/F	MDS	NR	AB/O	RIC	NR	CTX tacrolimus	NR	NR	NR	NR	D+270	2	After 2nd dose
Asawapanumas et al[11]	49/M	AML	MSD	B/O	MAC	NR	Pt-Cy; CSA; MMF	7.17	D+21	D+16	Tapering of IST	D+146	1	After 1st dose
Our patient	41/F	AML	MUD	AB/O	MAC	PBSC	MTX; CSA	4.67	D+11	D+12	Tapering of IST; PX; IFN; MNC	D+2701	5	After 2nd dose

M: Man; F: Female; MSD: Matched sibling donor; MUD: Matched, unrelated donor; MMF: Mycophenolat mofetil; PX: Plasma exchange; RIC: Reduced intensity conditioning; MAC: Myeloa-blative conditioning; IFN: Interferon; MNC: Mesenchymal stem cell; Haplo: Haploidentical allogeneic stem cell transplantation; DLI: Donor lymphocyte infusion; Pt-Cy: Post-transplantation cyclophosphamide; MMF: Mycophenolate mofetil; MTX: Methotrexate; CSA: Cyclosporine; CTX: Cyclophosphamide; IST: Immunosuppressive therapy.